Alzheimer’s disease quietly rewires the bone marrow, study finds

Alzheimer’s disease has long been studied almost exclusively as a disorder of the brain, a story of amyloid plaques, tau tangles and the slow failure of neurons. But a new study published in Nature Neuroscience argues that some of the most consequential damage may begin far outside the skull, in a place few neuroscientists thought to look: the bone marrow. The research shows that Alzheimer’s disease actively disrupts the production of myeloid immune cells in the marrow, starving the brain of protective reinforcements and allowing pathology to accelerate unchecked.

The central discovery is that a signaling molecule called type I interferon, released as part of the body’s innate antiviral and inflammatory response, acts as the culprit. In mouse models of Alzheimer’s amyloidosis, the researchers found that this signal hijacks the bone marrow’s myelopoiesis machinery, the carefully regulated production line that generates monocytes and other myeloid cells. The result is a fundamental reprogramming of the marrow: healthy monocyte output falls, and with it the supply of monocyte-derived macrophages that would normally travel through the bloodstream, cross into the brain and help clear amyloid deposits.

That supply chain matters more than many researchers once assumed. Microglia, the resident immune cells of the brain, mount the first line of defense against amyloid accumulation, but decades of evidence suggest they cannot manage the burden alone. Monocyte-derived macrophages act as reinforcements, arriving from the periphery when microglia fall short. Earlier work has shown that blocking the CCR2-dependent recruitment of these peripheral cells accelerates Alzheimer-like pathology in mice, a finding that hinted at their protective role. The new study explains one mechanism by which that reinforcement pipeline breaks down: the disease itself sabotages the factory that produces the workers.

The technical core of the research centers on the 5xFAD mouse model, a widely used strain engineered to carry mutations that drive aggressive amyloid-beta production and reproduce key features of Alzheimer’s pathology. Using this model, the team traced how type I interferon signaling reshapes hematopoiesis, the continuous process by which blood and immune cells are generated from hematopoietic stem cells in the marrow. Under chronic type I interferon exposure, the balance of myeloid cell output shifts away from the populations needed for brain defense, effectively redirecting the immune system’s production capacity at the worst possible moment.

The most striking result came from blocking the aberrant signal. When the researchers interfered with type I interferon signaling in the periphery of 5xFAD mice, healthy monocyte output from the bone marrow was restored. The consequences cascaded outward: protective monocyte-derived macrophages once again reached the brain, amyloid-related disease manifestations were alleviated, and the animals’ overall pathology improved. In other words, correcting a fault in the peripheral immune system produced measurable benefits in the brain, without directly targeting plaques, tau or neurons.

This finding reframes the therapeutic landscape. Most Alzheimer’s drug development has concentrated on the brain itself, targeting amyloid and tau directly or attempting to modulate neuroinflammation inside the central nervous system. The new work argues for a fundamentally different entry point: the peripheral immune system as a therapeutic target. If the marrow’s production line can be protected or restored, the brain’s own defenses might be reinforced from the outside in, complementing or even improving on approaches that act within neural tissue.

The idea that peripheral interferon signaling shapes brain health has been building for years. Prior research showed that an aging-induced type I interferon response at the choroid plexus, the interface that guards the brain’s fluid-filled ventricles, negatively affects brain function and contributes to cognitive decline, establishing that interferon signals at the brain’s borders can be harmful. Separate work demonstrated that activation of the cGAS–STING innate immune DNA-sensing pathway drives type I interferon signaling and contributes to pathology in 5xFAD mice. The new study extends this line of inquiry from the brain’s border checkpoints all the way back to the bone marrow, connecting these threads into a coherent peripheral-to-central narrative of immune dysfunction in Alzheimer’s disease.

Technically, the work exemplifies the growing field of neuroimmunology, which maps the dense bidirectional communication between the nervous system and the immune system. The bone marrow, blood, meninges and brain parenchyma form a continuous immune circuit, and disruptions at any node can propagate. Alzheimer’s disease, on this view, is not simply a neurodegenerative process with some incidental inflammation attached; it is a systemic condition in which the brain’s pathology actively reprograms distant immune organs, and in which those reprogrammed organs then fail to provide the support the brain desperately needs. The type I interferon axis appears to be a key transmission channel for this vicious cycle.

There are important caveats and open questions. The findings were established in the 5xFAD model, which reproduces amyloid-driven aspects of the disease but does not capture the full complexity of human Alzheimer’s, including tau pathology, neuronal loss and the disease’s heterogeneous course in people. Whether the same bone marrow myelopoiesis dysfunction occurs in human patients, and whether it correlates with disease stage, remains to be demonstrated. Translating the intervention to the clinic would also require identifying safe ways to modulate type I interferon signaling, a pathway central to antiviral immunity, without leaving patients vulnerable to infection or unleashing broader immune disruption.

Even so, the study opens an unusually concrete research agenda. Biomarkers of peripheral myelopoiesis could be developed to monitor immune reprogramming in patients, and drugs already approved for other interferon-driven conditions might be repurposed to test whether restoring marrow output benefits the brain. More broadly, the work adds Alzheimer’s disease to the growing list of neurological disorders, from multiple sclerosis to aging-related cognitive decline, in which the peripheral immune system is not a bystander but an active participant whose failure or manipulation shapes the course of disease. The bone marrow, long the province of hematologists, may soon claim a place in the neuroscience of dementia, as researchers pursue therapies that treat the brain’s defenses as a whole-body enterprise.

Subject of Research: Bone marrow myelopoiesis dysfunction and type I interferon signaling in Alzheimer's disease

Article Title: The hidden role of the bone marrow in Alzheimer’s disease

Article References: The hidden role of the bone marrow in Alzheimer’s disease. (2026). Nature Neuroscience. https://doi.org/10.1038/s41593-026-02418-6

Image Credits: AI Generated

DOI: 10.1038/s41593-026-02418-6

Keywords: Alzheimer's disease, bone marrow, type I interferon, myelopoiesis, monocyte-derived macrophages, neuroimmunology, 5xFAD mouse model, amyloid-beta, microglia, peripheral immune system, cGAS-STING, therapeutic target